Boehringer Ingelheim news from FierceBiotech
NewsALSO NOTED: Researchers testing stem cell therapy for CHF; Boehringer unveils new research center; and much more...
> Fifty-six of the nation's most creative biomedical scientists are being given the opportunity to tackle their most ambitious, risky research plans, as they become the newest class of Howard... Read more...
Boehringer boasts of late-stage drug potential
A new self-assessment from Boehringer Ingelheim comes with some considerable boasting about the potential for new therapies and new indications now in its pipeline.
Boehringer wins approval in anti-clotting drug race
Boehringer Ingelheim has stolen a march on arch rival Bayer, winning European marketing approval for a new anti-clotting agent--
Mystery suitor spurs spike in CeNeS stock
Shares of UK biotech CeNeS Pharmaceuticals rocketed up almost 70 percent after the developer confirmed that it's engaged in talks with a mystery suitor. CeNeS had little to offer to enlighten... Read more...
Biotech nonprofit to make meds with donated IP
The Connecticut biotech group CURE has set up a nonprofit subsidiary and staffed it with a couple of experienced R&D specialists out to turn the drug development world's cast-offs into low-cost... Read more...
A race to the finish for blockbuster blood thinners
Several big developers will take the stage at the American Society of Hematology meeting to provide updates on a string of new blood thinners that are in the clinic.
ALSO NOTED: CMC to boost production at Bothell facility; Eisai buys antibody; Vectura pockets milestone, equity pay; and much m
> The Copenhagen-based CMC Biopharmaceuticals says it plans to increase production of therapeutic proteins after buying the former Icos's plant in Bothell. Icos was acquired at the beginning of... Read more...
ALSO NOTED: Cipla, Akorn in development deal; No charges in Sepracor probe; Vectura raises funds; and much more...
> The FDA has warned GSK that its marketing for the breast cancer drug Tykerb is out of hand. Report... Read more...
Schering-Plough: A good company to work for
You may have a tough time finding a job at Amgen, but Science magazine's latest survey places the... Read more...
| Press ReleasesPRESS RELEASE: Boehringer Ingelheim Corporation's Aptivu Capsules Granted Full Approval by the U.S. FDA Boehringer Ingelheim Corporation's Aptivu Capsules Granted Full Approval by the U.S. FDA RIDGEFIELD, Conn., Oct. 5 -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food Read more >> PRESS RELEASE: The Lancet publishes major study of Boehringer Ingelheim's novel oral direct thrombin inhibitor dabigatran etexil The Lancet publishes major study of Boehringer Ingelheim's novel oral direct thrombin inhibitor dabigatran etexilate New drug effective in extended thromboprophylaxis following total hip replacement Read more >> PRESS RELEASE: Ablynx and Boehringer Ingelheim Announce Major Global Strategic Alliance Ablynx and Boehringer Ingelheim Announce Major Global Strategic Alliance to Discover, Develop and Commercialize Novel Nanobody Therapeutics GHENT/Belgium and INGELHEIM/Germany, 7 September 2007 - Read more >> |
Get more Boehringer Ingelheim coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
